NCT02500550COMPLETEDanonymous

An Exploratory, Open-label, Multicenter Study to Evaluate the Safety and Efficacy of a Two-dose Regimen of ATIR101, a T-lymphocyte Enriched Leukocyte Preparation Depleted ex Vivo of Host Alloreactive T-cells (Using Photodynamic Treatment), in Patients With a Hematologic Malignancy, Who Received a CD34-selected Hematopoietic Stem Cell Transplantation From a Haploidentical Donor

Sponsor

Source record

Kiadis Pharma

Phase

Source record

Phase 2

Modality

AI-normalized

protein therapy

Target

AI-normalized

T-lymphocyte enriched leukocyte preparation depleted ex vivo of host alloreactive T-cells (using photodynamic treatment)

Indication / condition

AI-normalized

Acute Myeloid Leukemia

Intervention

Source record

ATIR101, Haploidentical hematopoietic stem cell transplantation (HSCT), TBI regime, Non-TBI regime

Source & freshness

Source record

NCT ID

NCT02500550

Original source

ClinicalTrials.gov

Source last updated

May 18, 2021

Ingested at

Jun 13, 2026

Internal sync

Jun 13, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record

View original source fields

NCT ID

NCT02500550

Title

An Exploratory, Open-label, Multicenter Study to Evaluate the Safety and Efficacy of a Two-dose Regimen of ATIR101, a T-lymphocyte Enriched Leukocyte Preparation Depleted ex Vivo of Host Alloreactive T-cells (Using Photodynamic Treatment), in Patients With a Hematologic Malignancy, Who Received a CD34-selected Hematopoietic Stem Cell Transplantation From a Haploidentical Donor

Sponsor

Kiadis Pharma

Status

COMPLETED

Phase

Phase 2

Condition raw

Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome

Condition normalized

Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome

Modality raw

protein therapy

Modality normalized

protein therapy

Target raw

T-lymphocyte enriched leukocyte preparation depleted ex vivo of host alloreactive T-cells (using photodynamic treatment)

Target normalized

T-lymphocyte enriched leukocyte preparation depleted ex vivo of host alloreactive T-cells (using photodynamic treatment)

Interventions

ATIR101, Haploidentical hematopoietic stem cell transplantation (HSCT), TBI regime, Non-TBI regime

Public preview

Source record

ATIR101, developed by Kiadis Pharma, targets hematologic malignancies post haploidentical stem cell transplantation. The market for hematologic malignancies is substantial, with increasing demand for innovative therapies that reduce transplant-related complications such as graft-versus-host disease (GVHD). The competitive landscape includes other immunotherapies and stem cell transplant approaches. Successful outcomes from this trial could position Kiadis Pharma favorably against competitors, potentially leading to partnerships or acquisition interest. Diligence should focus on regulatory pathways and reimbursement strategies, given the complexity of the treatment regimen and patient population.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections

Patent/IP landscape with verified records when available

Board-ready PDF export with source provenance

Save to folders and synthesize multiple assets in premium workspace

Create account

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

An Exploratory, Open-label, Multicenter Study to Evaluate the Safety and Efficacy of a Two-dose Regimen of ATIR101, a T-lymphocyte Enriched Leukocyte Preparation Depleted ex Vivo of Host Alloreactive T-cells (Using Photodynamic Treatment), in Patients With a Hematologic Malignancy, Who Received a CD34-selected Hematopoietic Stem Cell Transplantation From a Haploidentical Donor

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 16, 2026

NCT ID

NCT02500550

Status

COMPLETED

Phase

Phase 2

Sponsor

Kiadis Pharma

Executive brief

Investment-Ready Snapshot

Source & freshness

Provenance

SourceClinicalTrials.gov

Source updatedMay 18, 2021

Internal syncJun 13, 2026

Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT02500550

Indication

Acute Myeloid Leukemia

Modality

protein therapy

Target

T-lymphocyte enriched leukocyte preparation depleted ex vivo of host alloreactive T-cells (using photodynamic treatment)

Intervention

ATIR101, Haploidentical hematopoietic stem cell transplantation (HSCT), TBI regime, Non-TBI regime

Source record